LONDON (Alliance News) - Scancell Holdings PLC said Tuesday that it had been granted a patent for its DNA ImmunoBody technology in Australia.
Scancell is an immunotherapy developer that produces vaccines for the treatment of cancer.
"Our lead ImmunoBody for melanoma, SCIB1, currently in Phase I/II clinical trials is based on the DNA approach," said Joint Chief Executive Dr.Richard Goodfellow in a statement. "The approval of this DNA patent is therefore a very important step in the development of our ImmunoBody platform. "
Scancell's shares were trading up 3.9% at 34.82 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.